Research programme: small molecule therapeutics - Prothena Corporation
Latest Information Update: 26 May 2021
At a glance
- Originator Prothena
- Class Antidementias; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Alzheimer's disease